Kidney Disease News and Research

RSS

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

Pre-implantation genetic diagnosis can avoid mother to child transmission of mtDNA disorders

Dutch researchers have developed a test which predicts which mothers at risk of passing on mitochondrial genetic disease to their children are likely to have a healthy baby.

30 May 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules, decreasing the effects of inflammation and fibrosis in acute kidney injury.

24 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Diet quality, not quantity, can make a difference in risk for type 2 diabetes

Small differences in diet - even without weight loss - can significantly affect risk for diabetes, according to research from the University of Alabama at Birmingham published online May 18, 2011, by the American Journal of Clinical Nutrition.

20 May 2011

Cholesterol drug may help treat mitochondrial diseases

A human drug that both prevents and cures kidney failure in mice sheds light on disabling human mitochondrial disorders, and may represent a potential treatment in people with such illnesses.

20 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Medical food resolves metabolic syndrome and cardiovascular risk factors

Researchers at the University of Florida and Metagenics Inc. today announced that a program consisting of a breakthrough medical food combined with a low-glycemic, Mediterranean-style diet is almost twice as effective as one of the best diets alone for lowering risk factors for cardiovascular disease, the leading cause of death in the U.S.

19 May 2011

Sensitive troponin assays improve clinical outcome and cardiac patient management

Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.

19 May 2011

Stem cells from kidneys - World first from Australian scientists

According to Australian scientists, their latest stem cell research breakthrough will bring new treatments for a growing epidemic of chronic kidney disease. They are the first in the world to generate a type of stem cell from human kidney cells. The Melbourne scientists are hoping their discovery will have far-reaching effects in treating the disease.

19 May 2011

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults.

From Quest Diagnostics 18 May 2011

Restrictive gadolinium-based contrast agent guidelines help prevent nephrogenic systemic fibrosis

A simple blood test may help prevent a serious complication associated with a contrast agent commonly used in MRI exams, according to a study published in the July issue of Radiology.

18 May 2011

Ampio's common stock to be listed on NASDAQ Capital Market

Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Scientists make human stem cells without working on human embryos

Stem cell research courts both controversy and support in the community- depending on your viewpoint.

17 May 2011

CorMedix first quarter net loss decreases to $1.9 million

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its financial results for the quarter ended March 31, 2011.

10 May 2011

Donors' genetic profile affects graft survival after kidney transplantation

A new study by researchers at Wake Forest Baptist Medical Center sheds light on what causes certain kidneys to do better than others after being transplanted, providing doctors with an easy way to screen for donor kidneys that have the best chance of survival.

10 May 2011

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant.

7 May 2011

Kidney Disease News and Research

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Pre-implantation genetic diagnosis can avoid mother to child transmission of mtDNA disorders

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Diet quality, not quantity, can make a difference in risk for type 2 diabetes

Cholesterol drug may help treat mitochondrial diseases

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Medical food resolves metabolic syndrome and cardiovascular risk factors

Sensitive troponin assays improve clinical outcome and cardiac patient management

Stem cells from kidneys - World first from Australian scientists

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Restrictive gadolinium-based contrast agent guidelines help prevent nephrogenic systemic fibrosis

Ampio's common stock to be listed on NASDAQ Capital Market

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Scientists make human stem cells without working on human embryos

CorMedix first quarter net loss decreases to $1.9 million

Donors' genetic profile affects graft survival after kidney transplantation

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News